Who is sponsoring DOAC-NOSTOP?

DOAC-NOSTOP is sponsored by Hospital Universitario La Fe.

What condition does DOAC-NOSTOP study?

DOAC-NOSTOP studies Coronary Artery Disease, Bleeding, Direct Acting Anticoagulant Adverse Reaction.

What drugs are being tested in DOAC-NOSTOP?

Interventions: Direct-acting oral anticoagulation.

What is the status of DOAC-NOSTOP?

DOAC-NOSTOP is currently UNKNOWN.

Last reviewed 2024-01-26 · How we verify

Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures (DOAC-NOSTOP)

NCT05292846 PHASE4 UNKNOWN

Up to 20-30% of patients who are candidates for direct oral anticoagulation (DOAC) present with concomitant ischemic heart disease and often require coronary angiography with or without percutaneous coronary intervention (PCI). The decision whether to continue the DOAC throughout periprocedural period or interrupt DOAC before planned procedure represents a substantial challenge in daily clinical practice. The objective of this study is to evaluate the safety of uninterrupted direct-acting oral anticoagulation in patients undergoing trans-radial percutaneous coronary procedures.

Details

Lead sponsor	Hospital Universitario La Fe
Phase	PHASE4
Status	UNKNOWN
Enrolment	200
Start date	Thu Jan 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Apr 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Coronary Artery Disease
Bleeding
Direct Acting Anticoagulant Adverse Reaction

Interventions

Direct-acting oral anticoagulation

Countries

Italy, Spain